Measurable or minimal residual disease (MRD) is the presence of very small numbers of tumor cells which may remain in the body following treatment. MRD testing currently has multiple clinical uses including the identification of disease relapse or in guiding patient treatment. MRD has traditionally been used in hematological indications but due to the increased availability of next generation sequencing (NGS) circulating tumor DNA (ctDNA) based testing, MRD is increasingly being leveraged in solid tumor indications.

During this webinar, our internal expert on MRD testing, Dr. Bob Holt (Senior Director, Precision Medicine Strategy Advisor) will give an overview of the current and future use of Minimal residual disease (MRD) in hematological and solid tumors. He will analyze the clinical utility, the technology available and barriers that can arise using MRD providing also insights into key factors on the use of MRD in clinical trials.

Following the webinar, Prof. Maria Teresa Voso from Tor Vergata University, Rome will present her daily routine (with pros and cons) of the use of MRD in AML opening a discussion with Bob Holt and all the attendees in the networking lounge.